MedTrace Logo

Dose Escalation of Different Concentrations of ZK 245186 in Atopic Dermatitis

NCT00944632 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2023-06-07

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and efficacy of three concentrations of ZK 245186 ointment and vehicle on increasing body surface areas for the treatment of atopic dermatitis and to obtain dose-response information for the three concentrations.

Conditions

Interventions

DRUG

ZK 245186

Once daily topical non-occlusive application for up to 4 weeks

DRUG

Placebo (vehicle ointment)

Once daily topical non-occlusive application for up to 4 weeks

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-15
Primary Completion
2010-09-15
Completion
2010-09-15

Countries

  • South Africa

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00944632 on ClinicalTrials.gov